Mga Batayang Estadistika
| LEI | 529900Q01Z5E3L6MZZ66 |
| CIK | 1403708 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Evoke Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 6, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 9, 2025 |
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI® Extending Orange Book listings to 2036 Extends patent exclusivity period an additional 6 years once granted SOLANA BEACH, Calif., July 9, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on |
|
| July 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 13, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Explanatory Note: This policy has been updated to reflect the one-for-twelve reverse stock split effected on August 1, 2024. |
|
| May 13, 2025 |
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K sal UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| March 13, 2025 |
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compel |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 22, 2024 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-281840 Prospectus Supplement (To Prospectus dated September 6, 2024 and Prospectus Supplement dated September 6, 2024) $3,145,322 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated September 6, 2024 and the prospectus supplement, dated September 6, 2024 (collectively, the “ATM Prosp |
|
| November 14, 2024 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex1.htm JOINT ACQUISITION STATEMENT Evoke Pharma Inc. Schedule 13G/A Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the |
|
| November 14, 2024 |
SC 13G/A 1 ep-sc13ga093024.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of thi |
|
| November 14, 2024 |
EVOK / Evoke Pharma, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evoke Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 30049G302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of regist |
|
| November 7, 2024 |
Exhibit 10.4 SEVENTH AMENDMENT TO LEASE This Seventh Amendment to Lease (this “Amendment”) is made, for reference purposes only, , by and between SB CORPORATE CENTRE III-IV, LLC, a Delaware limited liability company (“Landlord”), and EVOKE PHARMA, INC., a Delaware corporation (“Tenant”), with reference to the following facts: RECITALS 1. Landlord and Tenant are parties to that certain Office Lease |
|
| November 7, 2024 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and Matthew D’Onofrio (“Executive”), and shall be effective as of August 8, 2024 (the “Effective Date”). WHEREAS, Executive and the Company are parties to that certain Amende |
|
| November 7, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and Mark Kowieski (“Executive”), and shall be effective as of August 8, 2024 (the “Effective Date”). WHEREAS, the Company and Executive desire to amend and restate that certain Employment |
|
| November 7, 2024 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and Marilyn Carlson, M.D. (“Executive”), and shall be effective as of August 8, 2024 (the “Effective Date”). WHEREAS, the Company and Executive desire to amend and restate that certain Emp |
|
| November 7, 2024 |
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantl |
|
| November 6, 2024 |
EVOK / Evoke Pharma, Inc. / Nantahala Capital Management, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 2) (Rule 13d-101) Under the Securities Exchange Act of 1934 EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G203 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (Name, Address and Telephone Number of Person |
|
| October 29, 2024 |
EVOK / Evoke Pharma, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G302 (CUSIP Number) October 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 17, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 1, 2024 |
EVOK / Evoke Pharma, Inc. / Nantahala Capital Management, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2425294d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 1) (Rule 13d-101) Under the Securities Exchange Act of 1934 EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G203 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (Nam |
|
| September 27, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 27, 2024 |
Form of Exercise Price Warrant Amendment Exhibit 4.1 EVOKE PHARMA, INC. AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT, SERIES B COMMON STOCK PURCHASE WARRANTS, AND SERIES C COMMON STOCK PURCHASE WARRANT This Amendment (this “Amendment”) is made as of , 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and constitutes an amendment to that certain Series A Common Stock Purchase Warran |
|
| September 27, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-281527 Prospectus Supplement No. 1 (To Prospectus dated August 21, 2024) Evoke Pharma, Inc. This prospectus supplement updates, amends and supplements the prospectus dated August 21, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (Registration No. 333-281527). Capitalized terms used in this prospectus supp |
|
| September 27, 2024 |
Form of Series C Vesting Warrant Amendment Exhibit 4.2 EVOKE PHARMA, INC. AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANT This Amendment (this “Amendment”) is made as of , 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and constitutes an amendment to that certain Series C Common Stock Purchase Warrant (Warrant No.: C-[ ]), issued by the Company on February 13, 2024 (the “Series C War |
|
| September 27, 2024 |
Exhibit 10.1 September 27, 2024 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Re: Warrant Amendments, dated September 27, 2024, to those certain Series A Common Stock Purchase Warrants and Series C Common Stock Purchase Warrants Ladies and Gentlemen: Reference is made to those certain Warrant Amendments, dated September 27, 2024 (the “Warrant Amendments”), by and between |
|
| September 20, 2024 |
EVOK / Evoke Pharma, Inc. / Nantahala Capital Management, LLC - SC 13D Activist Investment SC 13D 1 tm2424509d1sc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No.) (Rule 13d-101) Under the Securities Exchange Act of 1934 EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G203 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (Name, Addr |
|
| September 20, 2024 |
EX-99.1 2 tm2424509d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Evoke Pharma, Inc., and further agree to the fi |
|
| September 4, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 September 4, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-3 File No. 333-281840 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024 As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. |
|
| August 29, 2024 |
EXHIBIT 4.9 EVOKE PHARMA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 5 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series. 6 Section 2.2. Establish |
|
| August 29, 2024 |
EXHIBIT 107 Calculation of Filing Fees Form S-3 (Form Type) Evoke Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee (4) Car |
|
| August 19, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 August 19, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-3 File No. 333-281527 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations u |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 13, 2024 |
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts submitted and accepted by the American Coll |
|
| August 13, 2024 |
As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration No. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 13, 2024 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company Exhibit 3.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOKE PHARMA, INC. Evoke Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Ev |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fees Table Form S-3 (Form Type) Evoke Pharma, Inc. |
|
| August 1, 2024 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOKE PHARMA, INC. Evoke Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Ev |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 20, 2024 |
Exhibit 4.1 EVOKE PHARMA, INC. AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT, SERIES B COMMON STOCK PURCHASE WARRANT AND SERIES C COMMON STOCK PURCHASE WARRANT This Amendment (this “Amendment”) is made as of [ ], 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and constitutes an amendment to that certain Series A Common Stock Purchase War |
|
| June 20, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 28, 2024 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOKE PHARMA, INC. Evoke Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Ev |
|
| May 28, 2024 | ||
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| May 14, 2024 |
Evoke Pharma Reports First Quarter 2024 Financial Results 114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif. |
|
| May 14, 2024 |
Manufacturing Services Agreement dated November 7, 2017, between the Company and Patheon UK Limited Exhibit 10.11 Manufacturing Services Agreement CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EVOKE PHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EVOKE PHARMA, INC. IF PUBLICLY DISCLOSED. Manufacturing Services Agreement 7 November 2017 Manufacturing Services Agreement Table of |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 14, 2024 |
EVOKE PHARMA, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97 EVOKE PHARMA, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Evoke Pharma, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Po |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 25, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-275443 Prospectus Supplement No. 2 (To Prospectus dated February 8, 2024) Evoke Pharma, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 8, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-275443). Capitalized terms used in this prospectus su |
|
| March 25, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 25, 2024 |
Exhibit 4.1 EVOKE PHARMA, INC. AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT, SERIES B COMMON STOCK PURCHASE WARRANT AND SERIES C COMMON STOCK PURCHASE WARRANT This Amendment (this “Amendment”) is made as of March , 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and constitutes an amendment to that certain Series A Common Stock Purchase Wa |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-275443 Prospectus Supplement No. 1 (To Prospectus dated February 8, 2024) Evoke Pharma, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 8, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-275443). Capitalized terms used in this prospectus su |
|
| March 14, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 EVOKE PHARMA, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Evoke Pharma, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Po |
|
| March 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 14, 2024 |
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results Fiscal year 2023 net product sales from prescriptions totaled approximately $5. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| March 14, 2024 |
Manufacturing Services Agreement dated November 7, 2017, between the Company and Patheon UK Limited Exhibit 10.11 Manufacturing Services Agreement CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EVOKE PHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EVOKE PHARMA, INC. IF PUBLICLY DISCLOSED. Manufacturing Services Agreement 7 November 2017 Manufacturing Services Agreement Table of |
|
| March 13, 2024 |
EVOK / Evoke Pharma, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evoke Pharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 30049G203 (CUSIP Number) February 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| March 11, 2024 |
EVOK / Evoke Pharma, Inc. / Bleichroeder LP - EVOK13G Passive Investment SC 13G 1 evok13g.htm EVOK13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Evoke Pharma, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 30049G203 (CUSIP Number) February 13, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 23, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 20, 2024 |
SC 13G 1 evok-sc13g020924.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G203 (CUSIP Number) February 9, 2024 (Date of Event |
|
| February 20, 2024 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-99.1 2 ex99-1.htm JOINT ACQUISITION STATEMENT EVOKE PHARMA, INC. SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the unde |
|
| February 14, 2024 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 14, 2024 |
Form of Representative Warrant Exhibit 4.1 FORM OF REPRESENTATIVE’S WARRANT AGREEMENT THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGH |
|
| February 13, 2024 |
US30049G2030 / EVOKE PHARMA INC / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EVOKE PHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30049G203 (CUSIP Number) February 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 9, 2024 |
Filed pursuant to Rule 424(b)(4) Registration Number 333-275443 Prospectus Evoke Pharma, Inc. |
|
| February 9, 2024 |
Exhibit 1.1 UNDERWRITING AGREEMENT between EVOKE PHARMA, INC. and CRAIG-HALLUM CAPITAL GROUP LLC LAIDLAW & COMPANY (UK) LTD. as Representatives of the Several Underwriters EVOKE PHARMA, INC. UNDERWRITING AGREEMENT New York, New York February 8, 2024 Craig-Hallum Capital Group LLC Laidlaw & Company (UK) Ltd. As the Representatives of the Several Underwriters Named on Schedule 1 hereto c/o Craig-Hal |
|
| February 9, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 9, 2024 |
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million Exhibit 99.1 Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million SOLANA BEACH, Calif., February 9, 2024 (GLOBE NEWSWIRE) - Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten |
|
| February 8, 2024 |
As filed with the Securities and Exchange Commission on February 8, 2024. As filed with the Securities and Exchange Commission on February 8, 2024. Registration No. 333-275443 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporati |
|
| February 7, 2024 |
[Remainder of Page Intentionally Left Blank] February 7, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 7, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 February 7, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General |
|
| January 17, 2024 |
[Remainder of Page Intentionally Left Blank] January 17, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| January 17, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 January 17, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 To the addressees set forth above: Reference is made to the letter from Ev |
|
| January 16, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 January 16, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General |
|
| January 16, 2024 |
[Remainder of Page Intentionally Left Blank] January 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 11, 2024 |
[Remainder of Page Intentionally Left Blank] January 11, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| January 11, 2024 |
As filed with the Securities and Exchange Commission on January 10, 2024. As filed with the Securities and Exchange Commission on January 10, 2024. Registration No. 333-275443 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporati |
|
| January 11, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 January 11, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 To the addressees set forth above: Reference is made to the letter from Ev |
|
| January 11, 2024 |
Calculation of Filing Fee Table Calculation of Filing Fee Tables S-1 (Form Type) Evoke Pharma, Inc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees Previously Paid Equity Common Stock Units, each consisting of (A) one share of Common Stock, par value $0. |
|
| January 11, 2024 |
UNDERWRITING AGREEMENT between EVOKE PHARMA, INC. and CRAIG-HALLUM CAPITAL GROUP LLC LAIDLAW & COMPANY (UK) LTD. as Representatives of the Several Underwriters |US-DOCS\146293200.10|| EVOKE PHARMA, INC. UNDERWRITING AGREEMENT New York, New York [ ], 2024 Craig-Hallum Capital Group LLC Laidlaw & Company (UK) Ltd. As the Representatives of the Several Underwriters Named on Schedule 1 hereto c/o Crai |
|
| January 11, 2024 |
Exhibit 4.4 SERIES B COMMON STOCK PURCHASE WARRANT EVOKE PHARMA, INC. Warrant Shares: Initial Exercise Date: [●] Issue Date: [●] THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●] (the |
|
| January 11, 2024 |
Exhibit 4.3 SERIES A COMMON STOCK PURCHASE WARRANT EVOKE PHARMA, INC. Warrant Shares: Initial Exercise Date: [●] Issue Date: [●] THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●] (the |
|
| January 11, 2024 |
Exhibit 4.5 SERIES C COMMON STOCK PURCHASE WARRANT EVOKE PHARMA, INC. Warrant Shares: Initial Exercise Date: [●] Issue Date: [●] THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●] (the |
|
| January 5, 2024 |
Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 January 5, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General R |
|
| January 5, 2024 |
[Remainder of Page Intentionally Left Blank] January 5, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 4, 2024 |
As filed with the Securities and Exchange Commission on January 4, 2024. As filed with the Securities and Exchange Commission on January 4, 2024. Registration No. 333-275443 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporatio |
|
| December 19, 2023 |
As filed with the Securities and Exchange Commission on December 19, 2023. As filed with the Securities and Exchange Commission on December 19, 2023. Registration No. 333-275443 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporat |
|
| December 19, 2023 |
Calculation of Filing Fee Table Calculation of Filing Fee Tables S-1 (Form Type) Evoke Pharma, Inc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| December 15, 2023 |
UNDERWRITING AGREEMENT between EVOKE PHARMA, INC. and CRAIG-HALLUM CAPITAL GROUP LLC LAIDLAW & COMPANY (UK) LTD. as Representatives of the Several Underwriters EVOKE PHARMA, INC. UNDERWRITING AGREEMENT New York, New York [ ], 2023 Craig-Hallum Capital Group LLC Laidlaw & Company (UK) Ltd. As the Representatives of the Several Underwriters Named on Schedule 1 hereto c/o Craig-Hallum Capital Group L |
|
| December 15, 2023 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EVOKE PHARMA, INC. Warrant Shares: Issue Date: [ ] Initial Exercise Date: [ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| December 15, 2023 |
Calculation of Filing Fee Table Calculation of Filing Fee Tables S-1 (Form Type) Evoke Pharma, Inc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| December 15, 2023 |
Exhibit 4.3 COMMON STOCK PURCHASE WARRANT EVOKE PHARMA, INC. Warrant Shares: Initial Exercise Date: [●] Issue Date: [●] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●] (the “Initial Exercise |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023. As filed with the Securities and Exchange Commission on December 15, 2023. Registration No. 333-275443 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporat |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2023 |
Evoke Pharma Reports Third Quarter 2023 Financial Results 38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, CA. |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023. As filed with the Securities and Exchange Commission on November 9, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-8447886 (State or other jurisdiction of incorporation or organization) (Prim |
|
| November 9, 2023 |
Calculation of Filing Fee Table Calculation of Filing Fee Tables S-1 (Form Type) Evoke Pharma, Inc (Exact Name of Registrat as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of regist |
|
| November 9, 2023 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease (this “Amendment”) is made, for reference purposes only, October 9, 2023, by and between SB CORPORATE CENTRE III-IV, LLC, a Delaware limited liability company (“Landlord”), and EVOKE PHARMA, INC., a Delaware corporation (“Tenant”), with reference to the following facts: RECITALS A. Landlord and Tenant are parties to that certain O |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 12, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 11, 2023 |
Calculation of Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Evoke Pharma, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Rule 457(c) an |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 10, 2023 |
Evoke Pharma Reports Second Quarter 2023 Financial Results 40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, CA. |
|
| August 10, 2023 |
Non-Employee Director Compensation Policy, as Amended and Restated Effective February 8, 2023 (i Exhibit 10.1 EVOKE PHARMA, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective February 8, 2023) Non-employee members of the board of directors (the “Board”) of Evoke Pharma, Inc. (the “Company”) shall be eligible to receive cash and equity compensation commencing on the Effective Date, as set forth in this Non-Employee Director Compensation Policy (this “Policy”). Th |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 EVOKE PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2023 |
Non-Employee Director Compensation Policy, as Amended and Restated Effective February 8, 2023 Exhibit 10.1 EVOKE PHARMA, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective February 8, 2023) Non-employee members of the board of directors (the “Board”) of Evoke Pharma, Inc. (the “Company”) shall be eligible to receive cash and equity compensation commencing on the Effective Date, as set forth in this Non-Employee Director Compensation Policy (this “Policy”). Th |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| May 15, 2023 |
Exhibit 99.1 Evoke Pharma Reports First Quarter 2023 Financial Results Net product sales increased by 94% from Q1 2022 New cumulative prescribers up by 17% from Q4 2022 Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) - Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestina |
|
| May 11, 2023 |
Evoke Pharma, Inc. 2013 Employee Stock Purchase Plan, as amended and restated effective May 10, 2023 Exhibit 10.2 EVOKE PHARMA, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (As Amended and Restated Effective May 10, 2023) Article 1. PURPOSE The purposes of this Evoke Pharma, Inc. 2013 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Evoke Pharma, Inc., a Delaware corporation (the “Company”), and its Designated Subsidiaries |
|
| May 11, 2023 |
Evoke Pharma, Inc. 2013 Equity Incentive Award Plan, as amended and restated effective May 10, 2023 Exhibit 10.1 EVOKE PHARMA, INC. 2013 EQUITY INCENTIVE AWARD PLAN (As Amended and Restated Effective May 10, 2023) ARTICLE 1. PURPOSE The purpose of the Evoke Pharma, Inc. 2013 Equity Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of Evoke Pharma, Inc. (the “Company”) by linking the individual interests of the me |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2023 Evoke Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 06, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 21, 2023 |
Exhibit 99.1 Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) - Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments |
|
| March 21, 2023 |
Exhibit 10.27 FIFTH AMENDMENT TO LEASE This Fifth Amendment to Lease (this “Amendment”) is made, for reference purposes only, August 24, 2022, by and between SB CORPORATE CENTRE III-IV, LLC, a Delaware limited liability company (“Landlord”), and EVOKE PHARMA, INC., a Delaware corporation (“Tenant”), with reference to the following facts: RECITALS A. Landlord and Tenant are parties to that certain |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2022 |
1 Exhibit 99.1 Evoke Pharma Reports Record Third Quarter 2022 Financial Results 80% increase in GIMOTI® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compared to Q2 13% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., November 9, 2022 (GLOBE NEWSWIRE) – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatment |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of regist |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Evoke Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36075 20-8447886 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2022 |
Exhibit 10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EVOKE PHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EVOKE PHARMA, INC. IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO THE COMMERCIAL SERVICES AGREEMENT THIS AMENDEMENT NO. 2 TO MASTER SERVICES AGREEMENT (this ? |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 EVOKE PHARMA, INC. |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 EVOKE PHARMA, INC. |
|
| August 10, 2022 |
1 99.1 Evoke Pharma Reports Second Quarter 2022 Financial Results Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%. SOLANA BEACH, Calif., August 10, 2022 (GLOBE NEWSWIRE) ? Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) disea |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 EVOKE PHARMA, INC. |
|
| August 10, 2022 |
Amended and Restated Certificate of Incorporation of the Company, as amended Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOKE PHARMA, INC. Evoke Pharma, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: 1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Ev |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 EVOKE PHARMA, INC. |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 EVOKE PHARMA, INC. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 EVOKE PHARMA, INC. |
|
| May 20, 2022 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOKE PHARMA, INC. Evoke Pharma, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: 1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Ev |
|
| May 10, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EVOKE PHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EVOKE PHARMA, INC. IF PUBLICLY DISCLOSED. amendment NO. 1 TO THE COMMERCIAL SERVICES AGREEMENT This Amendment No. 1 (?Amendment?), effective as of February 1, 2022 (t |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 EVOKE PHARMA, INC. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| May 10, 2022 |
Exhibit 99.1 Evoke Pharma Reports First Quarter 2022 Financial Results Several sales growth indicators increased over Q4, 2021: New Prescribers up 41%; Product delivered to patients up 39%; Net Revenue increased by 16%; Prescriptions written up 22% SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE ? Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatme |
|
| April 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 EVOKE PHARMA, INC. |
|
| April 26, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-251614 Prospectus Supplement (To Prospectus dated January 6, 2021) $9,152,176 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated January 6, 2021, filed as part of our registration statement on Form S-3 (File No. 333-251614), which we refer to as the sales agreement prospectus. The sales agree |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 EVOKE PHARMA, INC. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 15, 2022 |
DEF 14A 1 evok-def14a20220427.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 EVOKE PHARMA, INC. |
|
| March 8, 2022 |
Non-Employee Director Compensation Policy, as Amended and Restated Effective February 2, 2022 Exhibit 10.33 EVOKE PHARMA, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective February 2, 2022) Non-employee members of the board of directors (the ?Board?) of Evoke Pharma, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation commencing on the Effective Date, as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). T |
|
| March 8, 2022 |
Exhibit 99.1 Investor Contact: Daniel-Kontoh-Boateng DKB Partners Tel: 862-213-1398 [email protected] Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| March 8, 2022 |
Exhibit 10.34 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (this ?Amendment?) is made, for reference purposes only, February 3, 2022, by and between SB CORPORATE CENTRE III-IV, LLC, a Delaware limited liability company (?Landlord?), and EVOKE PHARMA, INC., a Delaware corporation (?Tenant?), with reference to the following facts: RECITALS A. Landlord and Tenant are parties to that certa |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 EVOKE PHARMA, INC. |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 EVOKE PHARMA, INC. |
|
| February 2, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 EVOKE PHARMA, INC. |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 EVOKE PHARMA, INC. |
|
| December 30, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 EVOKE PHARMA, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 EVOKE PHARMA, INC. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of regist |
|
| November 10, 2021 |
Evoke Pharma Reports Third Quarter 2021 Financial Results Exhibit 99.1 Investor Contact: Daniel-Kontoh-Boateng DKB Partners Tel: 862-213-1398 [email protected] Evoke Pharma Reports Third Quarter 2021 Financial Results SOLANA BEACH, CA, November 10, 2021 ? Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter end |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 EVOKE PHARMA, INC. |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 EVOKE PHARMA, INC. |
|
| August 12, 2021 |
Exhibit 99.1 Investor Contact: The Ruth Group Christine Petraglia Tel: 917-633-8980 [email protected] Media Contact: The Ruth Group Annika Parrish Tel: 720-412-9042 [email protected] Evoke Pharma Reports Second Quarter 2021 Financial Results Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti? Extends cash runway |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 EVOKE PHARMA, INC. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 EVOKE PHARMA, INC. |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 EVOKE PHARMA, INC. |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 EVOKE PHARMA, INC. |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 EVOKE PHARMA, INC. |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 EVOKE PHARMA, INC. |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 EVOKE PHARMA, INC. |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 EVOKE PHARMA, INC. |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 EVOKE PHARMA, INC. |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as specifi |
|
| May 12, 2021 |
Exhibit 99.1 Investor Contact: The Ruth Group Christine Petraglia / James Salierno Tel: 917-633-8980 / 973-255-8361 [email protected] / [email protected] Media Contact: The Ruth Group Annika Parrish Tel: 720-412-9042 [email protected] Evoke Pharma Reports First Quarter 2021 Financial Results Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increa |
|
| May 6, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Evoke Pharma, Inc. (Name of Issuer) Common Stock, $.0001 Par Value Per Share (Title of Class of Securities) 30049G104 (CUSIP Number) April 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| May 6, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 EVOKE PHARMA, INC. |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 EVOKE PHARMA, INC. |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 26, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No.1 Under the Securities Exchange Act of 1934 Evoke Pharma, Inc. (Name of Issuer) Common Stock, $.0001 Par Value Per Share (Title of Class of Securities) 30049G104 (CUSIP Number) March 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36075 Evoke Pharma, Inc. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 EVOKE PHARMA, INC. |
|
| March 11, 2021 |
Exhibit 99.1 Investor Contact: The Ruth Group Christine Petraglia / James Salierno Tel: 917-633-8980 / 973-255-8361 [email protected] / [email protected] Media Contact: The Ruth Group Annika Parrish Tel: 720-412-9042 [email protected] Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results Encouraging early traction from GIMOTI™ commercial launch SOLANA |
|
| March 11, 2021 |
Non-Employee Director Compensation Policy, as Amended and Restated Effective January 27, 2021 Exhibit 10.32 EVOKE PHARMA, INC. Non-Employee DIRECTOR COMPENSATION POLICY (As Amended and Restated Effective January 27, 2021) Non-employee members of the board of directors (the ?Board?) of Evoke Pharma, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation commencing on the Effective Date, as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). T |
|
| March 11, 2021 |
Exhibit 10.30 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this ?Amendment?) is made, for references purposes only, December 15, 2020, by and between SB CORPORATE CENTRE III-IV, LLC, a Delaware limited liability company (?Landlord?), and EVOKE PHARMA, INC., a Delaware corporation (?Tenant?), with reference to the following facts: RECITALS A. Landlord and Tenant are parties to that certa |
|
| January 20, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Evoke Pharma, Inc. (Name of Issuer) Common Stock, $.0001 Par Value Per Share (Title of Class of Securities) 30049G104 (CUSIP Number) January 14, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 14, 2021 |
Evoke Pharma Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Evoke Pharma Announces Proposed Public Offering of Common Stock SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE)—Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “firm commitment” underwritten public |
|
| January 14, 2021 |
Evoke Pharma Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 Evoke Pharma Announces Pricing of Public Offering of Common Stock SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE)—Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price |
|
| January 14, 2021 |
5,000,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251614 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JANUARY 6, 2021) 5,000,000 Shares of Common Stock We are offering 5,000,000 shares of our common stock at a purchase price of $2.50 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “EVOK.” On January 13, 2021, the last reported sale pric |
|
| January 14, 2021 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 EVOKE PHARMA, INC. |
|
| January 14, 2021 |
EX-1.1 Exhibit 1.1 5,000,000 Shares EVOKE PHARMA, INC. Common Stock UNDERWRITING AGREEMENT January 13, 2021 LAIDLAW & COMPANY (UK) LTD. 546 Fifth Avenue, 5th Floor New York, NY 10036 As Representative of the Several Underwriters named on Schedule A annexed hereto Ladies and Gentlemen: 1. Introductory. EVOKE PHARMA, INC., a Delaware corporation (the “Company”), agrees with Laidlaw & Company (UK) Lt |
|
| January 13, 2021 |
Results of Operations and Financial Condition, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 EVOKE PHARMA, INC. |
|
| January 13, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 13, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251614 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| January 4, 2021 |
CORRESP Evoke Pharma, Inc. 420 Stevens Avenue, Suite 370 Solana Beach, CA 92075 January 4, 2021 VIA EDGAR Mr. Alan Campbell Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-3 Filed December 22, 2020 File No. 333-251614 Dear Mr. Campbell: Pursuant to Rule 461 of Regulation C of the Gen |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 EVOKE PHARMA, INC. |
|
| December 22, 2020 |
EX-4.9 Exhibit 4.9 Evoke Pharma, Inc. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Es |
|
| December 22, 2020 |
EX-1.2 Exhibit 1.2 EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement December 22, 2020 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. |
|
| December 22, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 22, 2020 Registration No. |
|
| November 10, 2020 |
3PL Agreement between the Company and Eversana Life Science Services, LLC dated August 27, 2020 Exhibit 10.1 AS CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EVOKE PHARMA, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EVOKE PHARMA, INC. IF PUBLICLY DISCLOSED. This 3PL Agreement (the “Agreement”) is made on August 27, 2020 (the “Effective Date”) by and between: Evoke Pharma, Inc. |
|
| November 10, 2020 |
F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as s |
|
| November 10, 2020 |
Evoke Pharma Reports Third Quarter 2020 Financial Results Gimoti™ commercial launch underway Exhibit 99.1 Investor Contact: The Ruth Group Jan Medina, CFA Tel: 646-536-7035 [email protected] Media Contact: The Ruth Group Kirsten Thomas Tel: 508-280-6592 [email protected] Evoke Pharma Reports Third Quarter 2020 Financial Results Gimoti™ commercial launch underway SOLANA BEACH, CA, November 10, 2020 – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focuse |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 EVOKE PHARMA, INC. |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 EVOKE PHARMA, INC. |
|
| September 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 EVOKE PHARMA, INC. |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 EVOKE PHARMA, INC. |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 EVOKE PHARMA, INC. |
|
| August 6, 2020 |
Exhibit 99.1 Investor Contact: The Ruth Group Tram Bui Tel: 646-536-7035 [email protected] Evoke Pharma Reports Second Quarter 2020 Financial Results Preparing for commercial launch of GIMOTI™ in 4Q 2020 SOLANA BEACH, CA. August 6, 2020 – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financia |
